Investigational drug · Phase 2
CNP-104
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Primary Biliary Cholangitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "CNP-104"
First trial start
2022
Jan 25, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CNP-104", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Biliary Cholangitis
Approved drugs for the same conditions: Primary biliary cholangitis · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "CNP-104" as an intervention, largest first.
COUR Pharmaceutical Development Company, Inc.Industry
NCT05104853 · 42 participants · Start Jan 25, 2022 · Primary completion Jan 30, 2026
Drug: CNP-104; Placebo · For: Primary Biliary Cholangitis
Sites: Coronado, California; Lancaster, California; Sacramento, California · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Primary Biliary Cholangitis
- Saroglitazar MagnesiumPhase 35 trials
Zydus Therapeutics Inc. · Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis, Fibrosis
- VolixibatSHP626Phase 22 trials
Mirum Pharmaceuticals, Inc. · Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, PBC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.